Leader in the development of permanent seed brachytherapy in the treatment of cancer.
Physicians Clinicians
- Scientific Articles
- Cesium-131 Data
- Treatment Centers
- Physician Interviews
- Participating Centers
- Physician Information Form
- Release Criteria (PDF)
Physicians/Clinicians - Cesium-131 Data
Lung Data
- Cesium-I3I has delivered 90% of the intended dose 33 days post implant, compared to 32% of the I-125 dose.
- Cesium-I3I has delivered 99.8% of the dose at 90 days, when bioabsorbable sutures/mesh have most likely dissolved, compared to 65% of dose delivered for I-125.
- Cesium-I3I delivers uniform and symmetrical radiation penetration for a homogeneous lung implant.
- For the first 26 days after implant, the dose rate from Cs-I3I is greater than from I-125.
- After 26 days, the dose rate from I-125 implant exceeds that of Cs-I3I.
- With Cs-I3I, radiation safety precautions can be discontinued much sooner than with I-125.